CAMECO CORP (CCJ)       24.87  -0.07 (-0.28%)

24.87  -0.07 (-0.28%)

CA13321L1085 - Common Stock - Premarket: 25.04 +0.17 (+0.68%)


Fundamental Rating

6

Overall CCJ gets a fundamental rating of 6 out of 10. We evaluated CCJ against 380 industry peers in the Oil, Gas & Consumable Fuels industry. CCJ has a great financial health rating, but there are some minor concerns on its profitability. CCJ is valued quite expensive, but it does show an excellent growth.




Profitability

Profitability Rating

4

The Piotroski-F score of CCJ is 8.00. This is a very strong score and indicates great health and profitability for CCJ.
CCJ has a Return On Assets of 1.04%. This is below the industry average of 12.84%. 95% of the industry peers outperform CCJ.

CCJ has a Return On Equity of 1.53%. This is below the industry average of 28.11%. 97% of the industry peers outperform CCJ.
CCJ's Profit Margin of 4.78% is worse than the rest of the industry. The industry average Profit Margin is 25.86%. 87% of the industry peers have a better Profit Margin.
VS Industry

ROA (1.04%) VS Industry: 5% outperformed.

0.06
1,708.00

ROE (1.53%) VS Industry: 3% outperformed.

0.24
19,161.80

Profit Margin (4.78%) VS Industry: 13% outperformed.

0.07
334.14

Valuation

Valuation Rating

3

CCJ's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
With a price book ratio of 2.52, CCJ is valued correctly.
The Price/Earnings Ratio is 99.48, which means the current valuation is very expensive for CCJ.
With a Price/Earning Ratio of 99.48, CCJ is valued a higher than the industry average, which is at 5.70. 99% of the companies listed in the same industry are cheaper than CCJ!

With a Forward Price/Earnings Ratio of 34.61, CCJ is valued very expensively.
When comparing the price book ratio of CCJ to the average industry price book ratio of 1.43, CCJ is valued more expensive than its industry peers.
Compared to an average industry Enterprise Value to EBITDA ratio of 3.65, CCJ is valued more expensive than its industry peers. 99% of the companies listed in the same industry are valued cheaper.
VS Industry

Price/Earnings (99.48) VS Industry: 1% outperformed.

4,857.50
0.01

Price/Book (2.52) VS Industry: 25% outperformed.

3,894.73
0.04

Enterprise Value/ EBITDA (63.25) VS Industry: 1% outperformed.

235.61
0.36

Growth

Growth Rating

7

CCJ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 236.00%, which is quite impressive.
Measured over the past 5 years, CCJ shows a quite strong growth in Earnings Per Share. The EPS has been growing by 17.78% on average per year.
CCJ is expected to show a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 37.85% yearly.
When comparing the EPS growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.

The Revenue has grown by 26.65% in the past year. This is a very strong growth!
When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
Measured over the past 5 years, CCJ shows a decrease in Revenue. The Revenue has been decreasing by -2.84% on average per year.
CCJ is expected to show a small growth in Revenue. In the coming 5 years, the Revenue will grow by 6.72% yearly.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS17.78% 45.67% 236% 189.28% 123.59% 80.1% 37.85%
Revenue-2.84% 0.09% 26.65% 31.57% 15.94% 13.1% 6.72%

Health

Health Rating

9

A Current Ratio of 5.92 indicates that CCJ has no problem at all paying its short term obligations.
CCJ is one of the better placed companies in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 1.17. CCJ has a better rating than 87% of its industry peers.
CCJ has a Quick Ratio of 4.74. This indicates that CCJ is financially healthy and has no problem in meeting its short term obligations.
The Quick Ratio of CCJ is much better than the industry average of 1.03. CCJ has a better rating than 86% of its industry peers.

CCJ has an Altman-Z score of 4.20. This indicates that CCJ is financially healthy and little risk of bankruptcy at the moment.
CCJ is in better financial health than average in its industry. Its Altman-Z score is much better than the industry average of 2.07.
CCJ has a very good Piotroski-F score of 8.00. This indicates a great health and profitability for CCJ.
The Debt to Equity ratio of CCJ is in line with the industry averages.
VS Industry

Debt/Equity (0.17) VS Industry: 55% outperformed.

78.08
0.00

Quick Ratio (4.74) VS Industry: 86% outperformed.

0.00
279.52

Current Ratio (5.92) VS Industry: 87% outperformed.

0.00
279.52

Altman-Z (4.2) VS Industry: 76% outperformed.

-283,883.16
842.68

Dividend

Dividend Rating

5

The dividend of CCJ is nicely growing with an annual growth rate of 14.47%!
CCJ's earnings are growing more than its dividend. This makes the dividend growth sustainable.
CCJ has been paying a dividend for at least 10 years, so it has a reliable track record.
58.06% of the earnings are spent on dividend by CCJ. This is a bit on the high side, but may be sustainable.

With a yearly dividend of 0.32%, CCJ is not a good candidate for dividend investing.
With a Dividend Yield of 0.32, CCJ pays less dividend than the industry average, which is at 5.56. 100% of the companies listed in the same industry pay a better dividend than CCJ!
With a Dividend Yield of 0.32, CCJ pays less dividend than the S&P500 average, which is at 2.55.
VS Industry

Dividend Yield (0.32%) VS Industry: 0% outperformed.

0.32
64.51

CAMECO CORP24.87

NYSE:CCJ (3/20/2023, 8:04:00 PM)-0.07 (-0.28%)

Premarket: 25.04 +0.17 (+0.68%)

Chartmill FA Rating
GICS Sector Energy
GICS IndustryGroup Energy
GICS Industry Oil, Gas & Consumable Fuels
Earnings (Last) 02-09 2023-02-09/bmo Earnings (Next) 05-03 2023-05-03/bmo
Inst Owners 63.11% Inst Owner Change 15.26%
Ins Owners N/A Ins Owner Change N/A
Market Cap 10.76B Analysts 85
Price Target 35.09 (41.09%)

Dividend
Industry RankSector Rank
Dividend Yield 0.32%
Dividend Growth(5Y) 14.47% DP 58.06%
Div Incr Years 2 Div Non Decr Years 2
Ex-Date N/A

Surprises & Revisions
EPS beat(2) 1 Avg EPS beat(2) 59.12%
Min EPS beat(2) 59.12% Max EPS beat(2) 59.12%
EPS beat(4) 3 Avg EPS beat(4) 853.31%
Min EPS beat(4) 59.12% Max EPS beat(4) 2136.78%
Revenue beat(2) 1 Avg Revenue beat(2) 6.35%
Min Revenue beat(2) -3.49% Max Revenue beat(2) 16.2%
Revenue beat(4) 2 Avg Revenue beat(4) 6.95%
Min Revenue beat(4) -3.49% Max Revenue beat(4) 17.05%
PT rev (1m) 3.03% PT rev (3m) 3.92%
EPS NQ rev (1m) 11.58% EPS NQ rev (3m) 28.48%
EPS NY rev (1m) 20.97% EPS NY rev (3m) 20.97%
Revenue NQ rev (1m) 41.71% Revenue NQ rev (3m) 41.71%
Revenue NY rev (1m) 14.41% Revenue NY rev (3m) 14.41%

Valuation
Industry RankSector Rank
PE 99.48
Fwd PE 34.61
P/S 7.88
P/FCF 91.36
P/OCF 48.33
P/B 2.52
P/tB 2.54
EV/EBITDA 63.25
EPS(TTM) 0.25 EY 1.01%
EPS(NY) 0.72 Fwd EY 2.89%
FCF(TTM) 0.27 FCFY 1.09%
OCF(TTM) 0.51 OCFY 2.07%
SpS 3.16 BVpS 9.86
TBVpS 9.78 PEG (NY) 0.53
PEG (5Y) 5.59

Profitability
Industry RankSector Rank
ROA 1.04%
ROE 1.53%
ROIC 0.17%
ROICexc 0.23%
ROICexgc 0.23%
OM 0.91%
PM 4.78%
GM 12.49%
ROICexgc(3y) N/A ROICexcg growth 3Y -44.26%
ROICexcg growth 5Y -40.2% ROICexc(3y) N/A
ROICexc growth 3Y -44.22% ROICexc growth 5Y -40.17%
OM growth 3Y -45.2% OM growth 5Y -40.33%
PM growth 3Y 6.4% PM growth 5Y N/A
GM growth 3Y -1.25% GM growth 5Y -9.19%
F-Score 8 Asset Turnover 0.22

Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF 6.19
Debt/EBITDA 5.13
Cap/Depr 80.87%
Profit Quality 180.3%
Current Ratio 5.92
Quick Ratio 4.74
Altman-Z 4.2
F-Score 8 WACC 9.91%
ROIC/WACC 0.02 Cap/Depr(3y) 56.63%
Cap/Depr(5y) 42.81% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y 236% EPS 3Y 45.67%
EPS 5Y 17.78% EPS growth Q2Q 50%
EPS Next Y 189.28% EPS Next 2Y 123.59%
EPS Next 3Y 80.1% EPS Next 5Y 37.85%
Revenue growth 1Y 26.65% Revenue growth 3Y 0.09%
Revenue growth 5Y -2.84% Revenue growth Q2Q 12.74%
Revenue Next Year 31.57% Revenue Next 2Y 15.94%
Revenue Next 3Y 13.1% Revenue Next 5Y 6.72%
EBIT growth 1Y 112.89% EBIT growth 3Y -45.15%
EBIT growth 5Y -42.02% EBIT Next Year 420.39%
EBIT Next 3Y 135.15% EBIT Next 5Y 63.99%
FCF growth 1Y -55.17% FCF growth 3Y -29.08%
FCF growth 5Y -19.68% OCF growth 1Y -33.53%
OCF growth 3Y -16.7% OCF growth 5Y -12.57%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA